HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-31-2004, 12:13 AM   #1
Paul
Guest
 
Posts: n/a
Hybridon Inc. (Amex: HBY - News) announced today two presentations of preclinical data that showed Hybridon's immunomodulatory oligonucleotide (IMO(TM)) compounds inhibited tumor growth in mouse models of cancer. In these preclinical studies IMO monotherapy was shown to inhibit tumor growth in a syngeneic mouse melanoma model. The IMO when combined with Herceptin® in a mouse model of human breast cancer or Rituxan® in mouse models of non-Hodgkin's lymphoma potentiated the effectiveness of both monoclonal antibodies. The presentations were made at the 95th Annual Meeting of the American Association for Cancer Research being held in Orlando FL March 27-31.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:47 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter